Literature DB >> 8493572

Scientific and social issues of human immunodeficiency virus vaccine development.

B F Haynes1.   

Abstract

Development of a preventive immunogen for human immunodeficiency virus (HIV) infection is a national priority. The complexities associated with HIV host-virus interactions, coupled with the rapid progression of the HIV epidemic worldwide, have necessitated lowering expectations for an HIV vaccine that is 100 percent effective and have raised important scientific and nonscientific issues regarding development and use of preventive and therapeutic HIV vaccines.

Entities:  

Keywords:  Biomedical and Behavioral Research; Centers for Disease Control; Health Care and Public Health; National Institutes of Health

Mesh：

Substances：

Year:  1993        PMID： 8493572     DOI： 10.1126/science.8493572

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  20 in total

1.  HIV vaccine knowledge and beliefs among communities at elevated risk: conspiracies, questions and confusion.

Authors:  Kathleen Johnston Roberts; Peter A Newman; Naihua Duan; Ellen T Rudy
Journal:  J Natl Med Assoc       Date:  2005-12       Impact factor: 1.798

Review 2.  Progress and challenges toward an AIDS vaccine: Brother, can you spare a paradigm?

Authors:  W C Koff; A M Schultz
Journal:  J Clin Immunol       Date:  1996-05       Impact factor: 8.317

3.  Homologous recombination occurs in a distinct retroviral subpopulation and exhibits high negative interference.

Authors:  W S Hu; E H Bowman; K A Delviks; V K Pathak
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

4.  Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization.

Authors:  F Gao; S G Morrison; D L Robertson; C L Thornton; S Craig; G Karlsson; J Sodroski; M Morgado; B Galvao-Castro; H von Briesen; S Beddows; J Weber; P M Sharp; G M Shaw; B H Hahn
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

5.  Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; L Zaccaro; P Bandecchi; F Tozzini; M Bendinelli
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

6.  Evaluation of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte responses utilizing B-lymphoblastoid cell lines transduced with the CD4 gene and infected with HIV-1.

Authors:  M J McElrath; M Rabin; M Hoffman; S Klucking; J V Garcia; P D Greenberg
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

Review 7.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

8.  Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins.

Authors:  T C McGuire; D B Tumas; K M Byrne; M T Hines; S R Leib; A L Brassfield; K I O'Rourke; L E Perryman
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

9.  Chemiluminescent activation of the antiviral activity of hypericin: a molecular flashlight.

Authors:  S Carpenter; M J Fehr; G A Kraus; J W Petrich
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

Review 10.  HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1994-07       Impact factor: 2.332
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.